新闻
TARO
--
0.00%
--
BRIEF-Taro Pharmaceutical Industries Quarterly EPS $0.70
reuters.com · 1小时前
Taro Pharmaceutical GAAP EPS of $0.70 misses by $0.21, revenue of $138.98M misses by $3.24M
Taro Pharmaceutical press release (NYSE:TARO): FQ3 GAAP EPS of $0.70 misses by $0.21. Revenue of $138.98M (-0.8% Y/Y) misses by $3.24M.
Seekingalpha · 1小时前
Taro Pharmaceutical Indus Q3 EPS $0.70 Down From $0.86 YoY, Sales $139.00M Miss $142.22M Estimate
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.70 per share. This is a 18.6 percent decrease over earnings of $0.86 per share from the same period last year. The company reported quarterly sales
Benzinga · 1小时前
Taro Pharmaceutical Industries' Fiscal Q3 Earnings, Sales Decline
MT Newswires · 6小时前
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 10小时前
Taro Pharmaceutical Q3 2022 Earnings Preview
Taro Pharmaceutical (NYSE:TARO) is scheduled to announce Q3 earnings results on Thursday, January 27th, after market close. The consensus EPS Estimate is $0.91 (+37.9% Y/Y) and the consensus Revenue Estimate
Seekingalpha · 1天前
Notable earnings after Thursday's close
AAPL, AJG, AX, BOOT, BZH, CE, CLFD, CP, EBC, EMN, ETD, FHI, FICO, HITI, HOOD, JNPR, KLAC, MDLZ, MITK, NATI, OLN, RHI, RMD, RMR, SYK, TARO, TEAM, TFII, V, WAL,
Seekingalpha · 1天前
Is The Market Rewarding Taro Pharmaceutical Industries Ltd. (NYSE:TARO) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
It is hard to get excited after looking at Taro Pharmaceutical Industries' (NYSE:TARO) recent performance, when its...
Simply Wall St. · 2天前
Taro to Announce Third Quarter Results on January 27, 2022
HAWTHORNE, N.Y., January 21, 2022--Taro to Announce Third Quarter Results on January 27, 2022
Business Wire · 6天前
芋头制药 (TARO) 收益有望增长:您应该购买吗?
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 01/19 20:01
Taro (TARO) Surges 6.6%: Is This an Indication of Further Gains?
Taro (TARO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks · 01/05 12:48
Hot Stocks: AAPL touches $3T; retailers rally; GILT soars; TARO sets low; APLT drops on delayed application
The same optimistic view that fueled 2021's 27% advance in the S&P 500 carried over into the new year. With investor sentiment remaining strong, the major averages scored modest gains
Seekingalpha · 01/03 22:52
年初至今下跌超过 20%,抓住这 3 只买入评级的医疗保健股,争取 2022 年反弹
StockNews.com · 01/02 00:13
Down More Than 20% YTD, Grab These 3 Buy-Rated Healthcare Stocks for a 2022 Rebound
StockNews.com · 2021/12/27 15:22
The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 2021/12/02 12:51
太郎制药任命新的财务主管
Taro Pharmaceutical Industries (NYSE:TARO) appoints William J. Coote as Vice President, CFO and Chief Accounting Officer, effective today. Most recently, Mr. Coote has held progressively responsible positions with a variety of global companies
Seekingalpha · 2021/12/01 22:42
太郎药业(TARO)是一个很好的投资选择吗?
Raging Capital Management, an investment management firm, published its third-quarter 2021 investor letter – a copy of which can be downloaded here. The fund has compounded its returns at double-digits annually since its inception in 2006, but it plainly d...
Insider Monkey · 2021/11/15 17:15
Taro Pharmaceutical EPS misses by $0.36, misses on revenue
Taro Pharmaceutical (NYSE:TARO): Q3 GAAP EPS of $0.66 misses by $0.36. Revenue of $132M (-7.6% Y/Y) misses by $21.23M. Press Release
Seekingalpha · 2021/10/28 21:32
BRIEF-Taro Pharmaceutical Industries Reports Qtrly Sales Of $132 Million
reuters.com · 2021/10/28 21:17
Taro Pharmaceutical (TARO) Lags Q2 Earnings and Revenue Estimates
Zacks.com · 2021/10/28 05:31
微牛提供丰富的实时TARO股票新闻,让你可以通过多个平台了解TARO股票行情最新动态,这些免费的塔罗制药工业新闻可以帮助你做出明智投资。
TARO 简况
Taro Pharmaceutical Industries Ltd.(简称Taro)是一家科学制药公司。该公司主要通过三个实体从事经营:Taro Pharmaceutical Industries Ltd.(简称Taro Israel)和两个子公司 Taro Pharmaceuticals Inc.(简称Taro Canada)和Taro U.S.A.。该公司在超过25个国家销售超过200种药品。该公司拥有的产品品牌包括“Rokacet”,其通用名称为对乙酰氨基酚或可待因和咖啡因;“Topicort”,其通用名称为去羟米松;“Etopan”,其通用名为依托度酸;和“Ovide”,其通用名为马拉硫磷等。该公司的其他仿制药产品包括乙酰唑胺、阿达帕林、二丙酸阿氯米松、盐酸胺碘酮、乳酸铵、增强二丙酸倍他米松、盐酸西替利嗪、丙酸氯倍他索、盐酸氯米沙明、氯硝西泮二钾、氟尿嘧啶、酮康唑、甲硝唑、莫匹罗星和华法林钠等。